Two stocks in Healthcare
NEUCA vs Ypsomed Holding: profit, growth, debt and price compared
NEUCA is stronger on 4 of 7 figures: sales growth, price for its expected profit, dividend and analysts' view. Ypsomed Holding is stronger on 3: profit margin, debt and price trend.
Save both stocks to your watchlist and revisit their latest fundamentals.
| NEUCANEU.WA | Ypsomed HoldingYPSN.SW | |
|---|---|---|
| Net margin | 1.4% | Stronger: 24.6% |
| Revenue growth, past year | Stronger: +5.50% | −12.40% |
| Debt to equity | 45.2% | Stronger: 42.4% |
| Forward P/E | Stronger: 13.2× | 28.6× |
| Dividend yield | Stronger: 2.49% | 1.00% |
| Analysts | Stronger: Strong buy · 5 | Buy · 14 |
| From its 200-day average | −0.2% | Stronger: +19.6% |
Share price over the past year
- NEUCA−7.9%
- Ypsomed Holding+33.0%
19 Nov 202520 Nov 2026
NEUCA or Ypsomed Holding: which is stronger?
- YPSN.SW
Which is more profitable?
Ypsomed Holding keeps more of each sale as profit: 24.6% against 1.4%.
- NEU.WA
Which is growing its sales faster?
NEUCA is growing its sales faster: +5.50% over the past year, against −12.40%.
- YPSN.SW
Which has borrowed less?
Ypsomed Holding has borrowed less: its debt is 42.4% of what its shareholders own, against 45.2% for NEUCA.
- NEU.WA
Which costs less for the profit it is expected to make?
NEUCA costs less for the profit it is expected to make: 13.2× its forward earnings, against 28.6×.
- NEU.WA
Which pays more in dividends?
NEUCA pays more back in dividends for what a share costs: 2.49% a year, against 1.00%.
- NEU.WA
Which do analysts rate higher?
Analysts are warmer on NEUCA: Strong buy, against Buy for Ypsomed Holding.
- YPSN.SW
Which is in the stronger price trend?
Ypsomed Holding's price is in the stronger trend: 19.6% above its 200-day average, against 0.2% below.
What each company does
NEU.WANEUCA
NEUCA S.A. engages in the wholesale distribution of pharmaceuticals in Poland.
YPSN.SWYpsomed Holding
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication in Switzerland, Europe, North America, and internationally.
Reports results on 19 May 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.